Compare DexCom, Inc. (DXCM) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $90.57 (market cap $33.79B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.12. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | TLT | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $92.06 |
52-Week Low | $54.84 | $82.05 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.29 with a slight 0.3% daily gain amid bearish technical signals. The ETF faces pressure from rising long-term Treasury yields, with the 30-year yield recently hitting 5.24% (The Motley Fool, 2026-08-02). Institutional interest persists as Ferguson Shapiro LLC acquired 37,900 shares (Defense World, 2026-08-10), but outflows and U.S. debt nearing $40 trillion weigh on sentiment.
Outlook remains cautious as higher yields and inflation concerns challenge TLT's performance. Opportunities exist for income-focused investors given dividend payments, but risks include Fed rate hike potential and escalating geopolitical tensions driving oil prices higher. The bearish technical setup suggests continued pressure unless bond market sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
